We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.19%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$426M
AUM Growth
-$8.17M
Cap. Flow
-$21.9M
Cap. Flow %
-5.15%
Top 10 Hldgs %
33.1%
Holding
137
New
22
Increased
24
Reduced
54
Closed
27

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$7.8M
2
BIIB icon
Biogen
BIIB
+$7.48M
3
FOLD
Amicus Therapeutics
FOLD
+$6.39M
4
CYTK icon
Cytokinetics
CYTK
+$6.32M
5
TRVI icon
Trevi Therapeutics
TRVI
+$4.98M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$10.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.03M
3
NICE icon
Nice
NICE
+$5.13M
4
MRUS
Merus
MRUS
+$4.48M
5
SNY icon
Sanofi
SNY
+$4.34M

Sector Composition

Rank Sector Weight
1 Healthcare 65.73%
2 Technology 17.1%
3 Consumer Discretionary 1.67%
4 Utilities 1.53%
5 Communication Services 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
76
DELISTED
Astria Therapeutics
ATXS
$1.38M 0.32%
257,402
+67,602
+36% +$328K
KURA icon
77
Kura Oncology
KURA
$793M
$1.36M 0.32%
235,522
-108,000
-31% -$662K
IBIT icon
78
iShares Bitcoin Trust
IBIT
$47.2B
$1.31M 0.31%
21,455
+13,305
+163% +$746K
NTLA icon
79
Intellia Therapeutics
NTLA
$1.51B
$1.21M 0.28%
128,780
-252,300
-66% -$2.07M
VTYX
80
DELISTED
Ventyx Biosciences
VTYX
$1.19M 0.28%
555,814
-456,935
-45% -$738K
AMD icon
81
Advanced Micro Devices
AMD
$700B
$1.17M 0.27%
+8,250
New +$898K
NNDM
82
Nano Dimension
NNDM
$314M
$1.16M 0.27%
717,518
– –
DAWN
83
DELISTED
Day One Biopharmaceuticals
DAWN
$1.14M 0.27%
175,371
-159,616
-48% -$1.1M
CEVA icon
84
CEVA Inc
CEVA
$831M
$1.08M 0.25%
48,920
– –
CATX icon
85
Perspective Therapeutics
CATX
$327M
$1.07M 0.25%
310,343
-149,904
-33% -$396K
COGT icon
86
Cogent Biosciences
COGT
$6.76B
$1.03M 0.24%
143,693
-191,331
-57% -$1.06M
KRYS icon
87
Krystal Biotech
KRYS
$10.7B
$1.01M 0.24%
+7,335
New +$1.08M
TSHA icon
88
Taysha Gene Therapies
TSHA
$1.61B
$970K 0.23%
+420,000
New +$912K
PMN icon
89
ProMIS Neurosciences
PMN
$126M
$919K 0.22%
75,972
-1,200
-2% -$16.4K
VTGN icon
90
VistaGen Therapeutics
VTGN
$9.98M
$896K 0.21%
447,939
-342,611
-43% -$778K
CMMB
91
Chemomab Therapeutics
CMMB
$10.7M
$856K 0.2%
184,512
-40,595
-18% -$201K
BMY icon
92
Bristol-Myers Squibb
BMY
$129B
$810K 0.19%
17,500
-2,500
-13% -$123K
CRVS icon
93
Corvus Pharmaceuticals
CRVS
$1.1B
$732K 0.17%
183,094
-22,765
-11% -$82.8K
HOWL icon
94
Werewolf Therapeutics
HOWL
$22.4M
$683K 0.16%
626,810
– –
VSTM icon
95
Verastem
VSTM
$528M
$678K 0.16%
+163,307
New +$1.02M
BCAX
96
Bicara Therapeutics
BCAX
$1.7B
$610K 0.14%
+65,679
New +$783K
LRMR icon
97
Larimar Therapeutics
LRMR
$377M
$568K 0.13%
196,635
-169,669
-46% -$393K
S icon
98
SentinelOne
S
$6.35B
$494K 0.12%
+27,000
New +$494K
APRE icon
99
Aprea Therapeutics
APRE
$7.69M
$456K 0.11%
270,000
– –
CGNT icon
100
Cognyte Software
CGNT
$655M
$417K 0.1%
+45,181
New +$444K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return

Sphera Funds Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sphera Funds Management held 137 positions worth $426M, down 1.9% from $434M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $21.9M in Q2 2025, closing 27 positions and reducing 54 holdings. Its most notable exit was Nice, an estimated $5.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Amicus Therapeutics worth $5.68M.

  • Sphera Funds Management's largest Q2 2025 buy was Amicus Therapeutics: 990,718 shares worth $5.68M.
  • Sphera Funds Management added most to Tower Semiconductor in Q2 2025, an estimated $7.8M increase.
  • Sphera Funds Management's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $10.2M.
  • Sphera Funds Management fully exited Nice in Q2 2025, selling an estimated $5.13M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $426M portfolio in Q2 2025.
  • Sphera Funds Management opened 22 new positions and closed 27 in Q2 2025.
  • Sphera Funds Management's portfolio value fell 1.9% quarter-over-quarter to $426M.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.